KalVista Pharmaceuticals, Inc.
KALV
$13.05
-$0.26-1.95%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -44.85% | -62.39% | -55.49% | -48.95% | -36.31% |
| Total Depreciation and Amortization | 15.32% | 14.52% | 12.87% | 12.48% | 13.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -32.05% | 146.01% | 81.58% | 144.80% | 125.22% |
| Change in Net Operating Assets | -0.87% | 6,606.80% | 27.37% | 160.70% | 104.60% |
| Cash from Operations | -71.36% | -31.92% | -56.14% | -29.62% | -18.56% |
| Capital Expenditure | -933.33% | -75.00% | -77.17% | 79.79% | 96.49% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 208.01% | -189.57% | -218.61% | -314.65% | -298.72% |
| Cash from Investing | 207.44% | -190.29% | -219.30% | -316.79% | -304.56% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -36.79% | 25,356.66% | 75.30% | 74.89% | 70.13% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 84.55% | 49,351.00% | 4,796.13% | 4,796.13% | 4,796.13% |
| Cash from Financing | 5.98% | 52,244.08% | 164.45% | 163.98% | 159.33% |
| Foreign Exchange rate Adjustments | 317.56% | 25.40% | -2,542.86% | -171.13% | -198.14% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 510.99% | 333.71% | -184.30% | -252.10% | -195.86% |